A non-variable L1-peptide displays high sensitivity and specificity for detecting women having human papillomavirus-associated cervical lesions

Peptides

Volumn 29, Issue 6, 2008, Pages 957-962

  Urquiza, Mauricio ^a,b   Guevara, Tatiana ^a,b   Sanchez, Ricardo ^b   Vanegas, Magnolia ^a   Patarroyo, Manuel E ^a,b  

^a Fundation Instituto de Inmunología de Colombia   (Colombia)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

Cervical cancer; HPV infection; L1 peptides; Serological test

Indexed keywords

GLUTAMYLASPARTYLTHREONYLTYROSYLARGINYLPHENYLALANYLVALYLTHREONYL GLUTAMINYLALANYLISOLEUCYLALANYLCYSTEINYLGLUTAMINYLLYSYLHISTIDYLTHREONYL PROLYLPROLYLALANINE; LEUCYLTYROSYLISOLEUCYLLYSYLGLYCYLSERYLGLYCYLSERYLTHREONYLALANYL ASPARAGINYLLEUCYLALANYLSERYLSERYLASPARAGINYLTYROSYLPHENYLALANYLPROLYLTHREONINE; LYSYLALANYLLYSYLPROLYLLYSYLPHENYLALANYLTHREONYLLEUCYLGLYCYLLYSYL ARGINYLLYSYLALANYLTHREONYLPROLYLTHREONYLTHREONYLSERYLSERYLTYROSINE; PEPTIDE DERIVATIVE; PHENYLALANYLSERYLALANYLASPARTYLLEUCYLASPARTYLGLUTAMINYLPHENYLALANYL PROLYLLEUCYLGLYCYLARGINYLLYSYLPHENYLALANYLLEUCYLLEUCYLALANYLGLUTAMINYL GLYCYLLEUCYLTYROSINE; PROLYLASPARAGINYLASPARAGINYLASPARAGINYLLYSYLISOLEUCYLLEUCYLVALYL PROLYLLYSYLVALYLSERYLGLYCYLLEUCYLGLUTAMINYLTYROSYLARGINYLVALYLPHENYLALANYL ARGININE; PROLYLLYSYLGLUTAMYLASPARTYLASPARTYLPROLYLLEUCYLLYSYLLYSYLTYROSYL THREONYLPHENYLALANYLTRYPTOPHYLGLUTAMYLVALYLASPARAGINYLLEUCYLLYSYLGLUTAMYLLYSINE; PROLYLSERYLGLYCYLSERYLMETHIONYLVALYLTHREONYLSERYLASPARTYLALANYL GLUTAMINYLISOLEUCYLPHENYLALANYLASPARAGINYLLYSYLPROLYLTYROSYLTRYPTOPHYL LEUCYLGLUTAMININE; VIRUS ANTIBODY;

ADULT; ALPHA HELIX; ANTIGEN ANTIBODY REACTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC TEST; FEMALE; HUMAN; HUMAN TISSUE; INFECTION RISK; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEROLOGY; SERUM; UTERINE CERVIX CANCER; VERRUCA VULGARIS; VIRUS DETECTION; WART VIRUS;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; CASE-CONTROL STUDIES; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; REPRESSOR PROTEINS; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 43049089377     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2008.01.003     Document Type: Article

References (27)

1. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55 (2002) 244-265
2. Carter J.J., Wipf G.C., Benki S.F., Christensen N.D., and Galloway D.A. Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid L1 protein. J Virol 77 21 (2003) 11625-11632
3. Carter J.J., Koutsky L.A., Hughes J.P., Lee S.K., Kuypers J., Kiviat N., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181 6 (2000) 1911-1919
4. Carter J.J., Wipf G.C., Madeleine M.M., Schwartz S.M., Koutsky L.A., and Galloway D.A. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol 80 10 (2006) 4664-4672
5. Carter J.J., Koutsky L.A., Wipf G.C., Christensen N.D., Lee S.K., Kuypers J., et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174 5 (1996) 927-936
6. Cason J., Kambo P.K., Best J.M., and McCance D.J. Detection of antibodies to a linear epitope on the major coat protein (L1) of human papillomavirus type-16 (HPV-16) in sera from patients with cervical intraepithelial neoplasia and children. Int J Cancer 50 3 (1992) 349-355
7. Chen X.S., Garcea R.L., Goldberg I., Casini G., and Harrison S.C. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 5 3 (2000) 557-567
8. Combita A.L., Bravo M.M., Touze A., Orozco O., and Coursaget P. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in Colombian women with invasive cervical cancer. Int J Cancer 97 6 (2002) 796-803
9. de Gruijl T.D., Bontkes H.J., Walboomers J.M., Coursaget P., Stukart M.J., Dupuy C., et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome. J Gen Virol 80 (1999) 399-408
10. Houghten R.A. General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci USA 82 (1985) 5131-5135
11. Jacobs M.V., de Roda Husman A.M., van den Brule A.J., Snijders P.J., Meijer C.J., and Walboomers J.M. Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol 33 (1995) 901-905
12. Jacobs M.V., Snijders P.J., van den Brule A.J., Helmerhorst T.J., Meijer C.J., and Walboomers J.M. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 35 3 (1997) 791-795
13. Karem K.L., Poon A.C., Bierl C., Nisenbaum R., and Unger E. Optimization of a human papillomavirus-specific enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 9 3 (2002) 577-582
14. Kitchener H.C., Castle P.E., and Cox J.T. Achievements and limitations of cervical cytology screening. Vaccine 24 Suppl. 3 (2006) S63-S70 [Chapter 7]
15. Matsumoto K., Yasugi T., Oki A., Fujii T., Nagata C., Sekiya S., et al. IgG antibodies to HPV16, 52, 58 and 6 L1-capsids and spontaneous regression of cervical intraepithelial neoplasia. Cancer Lett 231 2 (2006) 309-313
16. Modis Y., Trus B.L., and Harrison S.C. Atomic model of the papillomavirus capsid. EMBO J 21 18 (2002) 4754-4762
17. Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 19 (2000) 1-5
18. Nonnenmacher B., Hubbert N.L., Kirnbauer R., Shah K.V., Munoz N., Bosch F.X., et al. Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. J Infect Dis 172 1 (1995) 19-24
19. Pagliusi S.R., Dillner J., Pawlita M., Quint W.G., Wheeler C.M., and Ferguson M. International Standard reagents for harmonization of HPV serology and DNA assays-an update. Vaccine 24 Suppl. 3 (2006) S193-S200 [Chapter 23]
20. Parkin D.M., Pisani P., and Ferlay J. Global cancer statistics. CA Cancer J Clin 49 (1999) 33-64
21. Rocha-Zavaleta L., Ambrosio J.P., Mora-Garcia Mde L., Cruz-Talonia F., Hernandez-Montes J., Weiss-Steider B., et al. Detection of antibodies against a human papillomavirus (HPV) type 16 peptide that differentiate high-risk from low-risk HPV-associated low-grade squamous intraepithelial lesions. J Gen Virol 85 Pt 9 (2004) 2643-2650
22. Sanclemente G., and Gill D.K. Human papillomavirus molecular biology and pathogenesis. J Eur Acad Dermatol Venereol 16 3 (2002) 231-240
23. Santamaria H., Manoutcharian K., Rocha L., Gonzalez E., Acero G., Govezensky T., et al. Identification of peptide sequences specific for serum antibodies from human papillomavirus-infected patients using phage display libraries. Clin Immunol 101 3 (2001) 296-302
24. Seedorf K., Oltersdorf T., Krammer G., and Rowekamp W. Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells. EMBO J 6 (1987) 139-144
25. Sharma B.K., Ray A., and Murthy N.S. Prevalence of serum antibodies to synthetic peptides to HPV16 epitopes among Indian women with cervical neoplasia. Eur J Cancer 32A 5 (1996) 872-876
26. Touze A., El Mehdaoui S., Sizaret P.Y., Mougin C., Munoz N., and Coursaget P. The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system. J Clin Microbiol 36 (1998) 2046-2051
27. Urquiza M., Guevara T., Espejo F., Bravo M.M., Rivera Z., and Patarroyo M.E. Two L1-peptides are excellent tools for serological detection of HPV-associated cervical carcinoma lesions. Biochem Biophys Res Commun 332 1 (2005) 224-232